Seattle Genetics (NASDAQ: SGEN) reported third-quarter earnings on Thursday, but while the biotech’s lead drug has been on the market for half a decade, it still remains largely a pipeline story. You have to skim down to the fourth subhead of the press release to get to the quarterly sales numbers.